Pacira BioSciences (PCRX) Following Pipeline Optimism Is The Stock Still Undervalued
Pacira BioSciences (PCRX) has drawn fresh attention after recent trading left the shares at US$25.36, with a market value near US$1.0b and mixed return patterns across different time frames.
Price action has been choppy. Pacira BioSciences shows a 1 day share price return of 0.79% and a 30 day share price return of 7.00%. However, the 1 year total shareholder return has declined 6.49%, which hints that recent momentum is still trying to repair longer term damage.
Scan how Pacira BioSciences compares with other potential turnaround stories by reviewing our curated list of 16 high quality undiscovered gems, which also pair established operations with under-the-radar share price performance.
Pacira BioSciences now trades below the average analyst target and at a steep discount to some fair value estimates. Is that a simple pricing gap, or a warning that the market is right to stay cautious?
Most Popular Narrative: 33.3% Undervalued
Against Pacira BioSciences' last close of $25.36, the most followed narrative pins fair value at $38.00, framing the stock as materially mispriced and tying that gap directly to how the current product portfolio is expected to scale.
Pacira's first-mover advantage and expanded clinical pipeline, including disease-modifying therapies like PCRX-201, validated by long-term, real-world outcomes registries and breakthrough designations, position it to capitalize on sustained, multi-decade growth in global surgical volumes and opioid-sparing pain management, supporting stepwise expansion in addressable markets and top-line growth far above current market assumptions.
Curious what kind of revenue climb, profit margin reset, and future earnings multiple this narrative builds in. The Pacira BioSciences blueprint leans on aggressive earnings compounding, tighter share count, and a valuation reset that pulls the P/E closer to more established peers without assuming a premium.
Result: Fair Value of $38 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the Pacira BioSciences story can break if patent or reimbursement setbacks hit EXPAREL, or if its concentrated product portfolio stumbles in key procedures.
Find out about the key risks to this Pacira BioSciences narrative.
Another View on Pacira BioSciences Valuation
The earlier narrative leans on future earnings and a target P/E to discuss whether Pacira BioSciences looks mispriced. On current numbers, the picture is less generous. The stock trades on a P/E of 69.1x versus 16x for the US Pharmaceuticals industry and 15.1x for peers. The fair ratio is presented as 19x, which points to meaningful valuation risk if sentiment cools.
That gap means investors are already paying a heavy premium for the earnings that do exist, even though Pacira BioSciences only just turned profitable and currently reports a 2.2% return on equity. The key question is whether future growth can keep that multiple from compressing.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages around Pacira BioSciences can be useful if you move quickly and evaluate each point against the underlying numbers yourself, including the 3 key rewards and 1 important warning sign
Looking for more Pacira BioSciences sized opportunities?
If Pacira BioSciences has you thinking about risk, reward, and timing, do not stop here. Fresh ideas are where future gains often start taking shape.
- Target potential mispricing by scanning the 31 high quality undervalued stocks that combine solid fundamentals with prices that still look out of step with their underlying strength.
- Prioritize resilience first and cut down on unpleasant surprises by reviewing the 11 resilient stocks with low risk scores filtered for steadier financial profiles and lower risk scores.
- Hunt for future standouts early by working through the 21 elite penny stocks with strong financials that already show stronger financial traits than a typical low priced ticker.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com